I have been the Head of the Research Team at PCMA, representing the pharmacy benefit industry, for nearly four years. And while it is part

A recent paper from Dr. Casey Mulligan examines the services that PBMs provide, estimating they create $145 billion in value to society annually. This value translates into a 7:1 return on investment each year.

PCMA is releasing ten years of independent and chain retail pharmacy count data for every state. The number of independent retail pharmacies nationwide increased 8% over the last ten years, and 1.2% over the last five years, suggesting a stable marketplace.

Over the last five years, the marketplace for independent pharmacies has experienced small fluctuations from year-to-year sometimes gaining stores, sometimes losing stores. These recent fluctuations in the overall number of stores have not dramatically shifted the independent pharmacy market.

Thanks to PBMs’ efforts to give patients an incentive to use them and pharmacies an incentive to purchase them at the lowest prices, generics are widely available and affordable for hundreds of millions of Americans.

Using data from CMS, we see increases in the average plan contract-level beneficiary adherence to hypertension medication. Gains in adherence translates to real people staying on their medications and having better health outcomes.